Search results for "Gastrinoma"

showing 7 items of 7 documents

MEN1 Disease Occurring Before 21 Years Old: A 160-Patient Cohort Study From the Groupe d'étude des Tumeurs Endocrines

2015

Multiple endocrine neoplasia Type-1 (MEN1) in young patients is only described by case reports.To improve the knowledge of MEN1 natural history before 21 years old.Obtain a description of the first symptoms occurring before 21 years old (clinical symptoms, biological or imaging abnormalities), surgical outcomes related to MEN1 Neuro Endocrine Tumors (NETs) occurring in a group of 160 patients extracted from the "Groupe d'étude des Tumeurs Endocrines" MEN1 cohort.The first symptoms were related to hyperparathyroidism in 122 cases (75%), pituitary adenoma in 55 cases (34%), nonsecreting pancreatic tumor (NSPT) in 14 cases (9%), insulinoma in 20 cases (12%), gastrinoma in three cases (2%), mal…

AdenomaAdultMalemedicine.medical_specialtyAdolescentendocrine system diseasesAdenomaEndocrinology Diabetes and MetabolismClinical BiochemistryAdrenal Gland NeoplasmsContext (language use)BiochemistryCohort StudiesYoung AdultEndocrinologyPancreatic tumorPituitary adenomaInternal medicineMultiple Endocrine Neoplasia Type 1medicineHumansPituitary NeoplasmsAge of OnsetChildMultiple endocrine neoplasiaGastrinomabusiness.industryBiochemistry (medical)Infantmedicine.diseasePancreatic NeoplasmsNeuroendocrine TumorsEndocrinologyChild PreschoolFemaleInsulinomaFranceAge of onsetbusinessCohort studyThe Journal of Clinical Endocrinology & Metabolism
researchProduct

European disparities in malignant digestive endocrine tumours survival.

2009

The aim of this study was to report on malignant digestive endocrine tumours (MDET) prognosis in several European countries. We analysed survival data from 19 cancer registries in 12 European countries on 3,715 MDET diagnosed between 1985 and 1994. The overall 5-year survival rate was 47.5%. It was 58.1% for differentiated MDET and 8.1% for small-cell MDET (p < 0.001), 55.9% for patients under 65 and 37.0% for older patients. Survival rates for small intestinal and colorectal were higher than for the other sites. The 5-year relative survival rates were 60.3% in Northern Europe, 53.6% in Western Continental Europe, 42.5% in the UK, 37.6% in Eastern Europe (p < 0.001). Among well-differentiat…

MaleCancer Researchmedicine.medical_specialtyPathologyGlucagonomaDigestive System NeoplasmsGastroenterologydigestive endocrine tumours survivalInternal medicineEndocrine Gland NeoplasmsmedicineHumansCarcinoid tumourRegistriesSurvival rateAgedNeoplasm StagingGastrinomaRelative survivalbusiness.industryAbsolute risk reductionCancerMiddle Agedmedicine.diseasePrognosisCancer registryEuropeSurvival RateOncologyFemalebusinessInternational journal of cancer
researchProduct

The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?

2018

Purpose: Analyze the role of somatostatin analogues (SSAs) in the treatment of sporadic and MEN1-related gastrinomas, trying to define whether recent trials have changed the landscape of gastrinoma therapy. Methods: We evaluate the rationale of SSA use in the treatment of gastrinomas, summarize the current literature concerning the effect of SSAs on the control of Zollinger-Ellison syndrome (ZES) and gastrinomas tumor progression and discuss their role in the most recent guidelines. Results: The medical treatment of gastrinoma and related ZES is aimed at controlling acid hypersecretion and tumor progression, in inoperable patients. The use of proton pump inhibitors (PPIs) to control the syn…

Oncologymedicine.medical_specialtyProton Pump InhibitorAntineoplastic Agents HormonalEndocrinology Diabetes and MetabolismGastrinoma; neuroendocrine tumours; somatostatin; somatostatin analogues; endocrinology; diabetes and metabolism; endocrinologyNeuroendocrine tumorssomatostatinOctreotideSomatostatin analogueSettore MED/13 - EndocrinologiaZollinger-Ellison Syndrome03 medical and health sciencesendocrinology0302 clinical medicineInternal medicineNeuroendocrine tumourmedicineHumansProgression-free survivaldiabetes and metabolismGastrinomaMedical treatmentsomatostatin analoguesbusiness.industryDisease progressionPancreatic NeoplasmProton Pump Inhibitorsmedicine.diseasedigestive system diseasesZollinger-Ellison syndromePancreatic NeoplasmsEndocrinologySomatostatinTreatment OutcomeTumor progression030220 oncology & carcinogenesisGastrinoma030211 gastroenterology & hepatologyneuroendocrine tumoursbusinessHuman
researchProduct

Trattamento con lanreotide di un caso di gastrinoma già trattao con 177Lu-DOTATATE

2009

gastrinoma MEN-1Settore MED/13 - Endocrinologia
researchProduct

Safety of high doses of somatostatin analogs in well differentiated NENs in elderly

2019

Abstract Background Neuroendocrine neoplasms (NENs) are a group of heterogeneous neoplasms which can be treated with different therapies: in well differentiated (WD) NENs analogs of somatostatin (SSA) can be used considering their proved antineoplastic and antisecretory effects. This is a multicenter study to investigate the safety of high doses (HDD) analogs of somatostatin (SSA) in WD NENs with particular attention for patients over 70 years of age. Methods We collected clinical data from 13 Italian NENs dedicated Units. Patients with WD NENs, in progression on previous treatments, included SSA, and subsequently treated with HDD-SSA, were considered. Results 170 pts were included: 61.76% …

medicine.medical_specialtyGastrinomabusiness.industryHematologyNeuroendocrine tumorsmedicine.diseaseGastroenterologyZollinger-Ellison syndromeSteatorrheaOncologyInternal medicineCholecystitisMedicinemedicine.symptombusinessInsulinomaCarcinoid syndromeMalignant Carcinoid SyndromeAnnals of Oncology
researchProduct

Gastrin: an acid-releasing, proliferative and immunomodulatory peptide?

2010

Gastrin release is affected by gastric inflammatory conditions. Antral G cells respond to inflammatory mediators by increasing gastrin secretion. Accumulating experimental evidence suggests that gastrin exerts immunomodulatory and proinflammatory effects. Gastrin could be a contributing factor to these pathologies, which may constitute a new justification for pharmacological blockade of gastrin action.

medicine.medical_specialtyInflammationdigestive systemProinflammatory cytokineGastric AcidImmunomodulationInternal medicineDrug DiscoveryGastrinsmedicineAnimalsHumansSecretionGastrin-Secreting CellsProtein PrecursorsAntrumGastrinCell ProliferationPharmacologyChemistrydigestive oral and skin physiologyGeneral MedicineBlockadeImmunomodulatory peptideEndocrinologyGastrinomaGastritisReceptors CholecystokininG cellmedicine.symptomhormones hormone substitutes and hormone antagonistsSignal TransductionMini reviews in medicinal chemistry
researchProduct

Duodenal perforation as presentation of gastric neuroendocrine tumour: A case report

2020

Highlights • Gastric neuroendocrine neoplasms (g-NENs) represent the most frequent digestive NENs and are increasingly recognized thanks to diffusion of upper gastrointestinal endoscopy. • g-NENs can be sporadic or associated with multiple endocrine neoplasia type 1 (MEN-1) and present with a functional Zollinger-Ellison syndrome. • We described a case of a 60 years old Caucasian male came to emergency room with diffuse abdominal pain and leukocytosis on blood tests. • At the level of the pyloric portion we found irregularly thickened walls associated with a small fluid collection and bubbles of free air. On exploratory laparoscopy we found a large perforation (about 5 cm of size) in the fi…

medicine.medical_specialtyPerforation (oil well)Case ReportNeuroendocrine tumorsAsymptomaticGastroenterologyExploratory laparoscopyGastric perforation03 medical and health sciences0302 clinical medicineInternal medicinemedicineMultiple endocrine neoplasiaDuodenal PerforationGastrinomabusiness.industrymedicine.diseasedigestive system diseasesZollinger-Ellison syndrome030220 oncology & carcinogenesisGastric NETEmergency surgery030211 gastroenterology & hepatologySurgerymedicine.symptombusinessCarcinoid syndrome
researchProduct